Several groups reported that treatment of T1D with mAb specific to CD3 resulted in a significant therapeutic effect through the antigenic modulation of the TCR-CD3ζ complex (reviewed in [40]). This evidence concerns the gene CD247 and type 1 diabetes mellitus.